Comparison of efficacies of a dipeptidyl peptidase 4 inhibitor and α-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice

DOI Web Site PubMed 被引用文献4件 参考文献61件

書誌事項

タイトル別名
  • Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and .ALPHA.-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice
  • Comparison of efficacies of a dipeptidyl peptidase 4 inhibitor and a glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice
  • Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice

この論文をさがす

抄録

E3024 (3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate) is a dipeptidyl peptidase IV (DPP-IV) inhibitor. Since the target of both DPP-IV inhibitors and α-glucosidase inhibitors is the lowering of postprandial hyperglycemia, we compared antihyperglycemic effects for E3024 and α-glucosidase inhibitors in various oral carbohydrate and meal tolerance tests using normal mice. In addition, we investigated the combination effects of E3024 and voglibose on blood glucose levels in a meal tolerance test using mice fed a high-fat diet. ER-235516-15 (the trifluoroacetate salt form of E3024, 1 mg/kg) lowered glucose excursions consistently, regardless of the kind of carbohydrate loaded. However, the efficacy of acarbose (10 mg/kg) and of voglibose (0.1 mg/kg) varied with the type of carbohydrate administered. The combination of E3024 (3 mg/kg) and voglibose (0.3 mg/kg) improved glucose tolerance additively, with the highest plasma active glucagon-like peptide-1 levels. This study shows that compared to α-glucosidase inhibitors, DPP-IV inhibitors may have more consistent efficacy to reduce postprandial hyperglycemia, independent of the types of carbohydrate contained in a meal, and that the combination of a DPP-IV inhibitor and an α-glucosidase inhibitor is expected to be a promising option for lowering postprandial hyperglycemia.<br>

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (61)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ